dc.contributor.author | Stikbakke, Einar | |
dc.contributor.author | Schirmer, Henrik | |
dc.contributor.author | Knutsen, Tore | |
dc.contributor.author | Støyten, Martin | |
dc.contributor.author | Wilsgaard, Tom | |
dc.contributor.author | Giovannucci, Edward L. | |
dc.contributor.author | McTiernan, Anne | |
dc.contributor.author | Eggen, Anne Elise | |
dc.contributor.author | Haugnes, Hege Sagstuen | |
dc.contributor.author | Richardsen, Elin | |
dc.contributor.author | Thune, Inger | |
dc.date.accessioned | 2022-01-28T12:54:24Z | |
dc.date.available | 2022-01-28T12:54:24Z | |
dc.date.issued | 2021-12-22 | |
dc.description.abstract | Background: Inflammation has been linked to prostate cancer and hypertension, but it remains equivocal whether elevated blood pressure (BP) influence
prostate cancer risk and survival.<p>
<p>Method: Using Cox regression models, we examined the association between
prediagnostic BP and prostate cancer risk among 12,271 men participating in the
Prostate Cancer throughout life (PROCA-life) study. Systolic and diastolic BP
were measured. A total of 811 men developed prostate cancer, and followed for
additional 7.1 years, and we studied the association between prediagnostic BP
and overall mortality among patients with prostate cancer.<p>
<p>Results: Men (>45 years) with a systolic BP >150 mmHg had a 35% increased risk
of prostate cancer compared with men with a normal systolic BP (<130 mmHg)
(HR 1.35, 95% CI 1.08–1.69). Among patients with prostate cancer, men with systolic BP >150 mmHg had a 49% increased overall mortality compared with
men with a normal systolic BP (HR 1.49, 1.06–2.01). Among patients with prostate
cancer treated with curative intent, those with a high diastolic BP (>90 mmHg)
had a threefold increase in overall mortality risk (HR 3.01, 95% CI 1.40–6.46)
compared with patients with a normal diastolic BP (<80 mmHg).<p>
<p>Conclusion: Our results support that systolic and diastolic BP are important factors when balancing disease management in patients with prostate cancer. | en_US |
dc.identifier.citation | Stikbakke, Schirmer, Knutsen, Støyten, Wilsgaard, Giovannucci, McTiernan, Eggen, Haugnes, Richardsen, Thune. Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival. The PROCA-life study. Cancer Medicine. 2021 | en_US |
dc.identifier.cristinID | FRIDAID 1976902 | |
dc.identifier.doi | 10.1002/cam4.4523 | |
dc.identifier.issn | 2045-7634 | |
dc.identifier.uri | https://hdl.handle.net/10037/23833 | |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.relation.ispartof | Stikbakke, E. (2022). Inflammation, hypertension, and microRNA and Prostate Cancer. The Prostate Cancer throughout life (PROCA-life) study. (Doctoral thesis). <a href=https://hdl.handle.net/10037/24212>https://hdl.handle.net/10037/24212</a>. | |
dc.relation.journal | Cancer Medicine | |
dc.relation.projectID | info:eu-repo/grantAgreement/RCN/?/?/Norway/?/?/ | en_US |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2021 The Author(s) | en_US |
dc.title | Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival. The PROCA-life study | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |